We Haven’t Ruled Out Drug Price Increases, Says Regeneron’s Schleifer
Executive Summary
In an exclusive interview, one of the most direct CEOs in the industry, Regeneron’s Len Schleifer, clarifies his attitude to drug pricing and growing internal innovation.
You may also be interested in...
US Drug Pricing Challenges Poised To Impact Pharma Growth, Leerink Warns
Drug price increases have contributed significantly to US revenue growth, about 61% for the 45 largest pharmaceutical products sold over the last three years, according to an analysis by Leerink. Investors should brace for declining growth rates for certain products that generate the bulk of their sales in the US, analyst Geoffrey Porges warned.
Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer
In addition to skin cancer, the PD-1 inhibitor cemiplimab is being positioned for a range of other tumor types with Phase III studies ongoing in lung and cervical cancers.
Regeneron And Bluebird Team Up In Cell Therapy "Joint Venture"-Style Deal
Regeneron will make a $100m equity investment in bluebird to collaborate on the discovery of antibodies and T cell receptors, with the hope of building out in immuno-oncology and overcoming some of the early cell therapy challenges. Regeneron's business development chief talks to Scrip about its strategy.